An AI startup called Lillia, which is revolutionizing chronic care for a healthier world, today unveiled its platform, which enables people with diabetes and other chronic illnesses to lead happy, fulfilling lives.
Lillia’s AI-powered, clinically validated platform helps public sector organizations, businesses, insurers, and healthcare providers effectively manage chronic illnesses.
“Diabetes and related chronic conditions are the world’s biggest healthcare challenge, affecting more than 500 million people. The good news is with the right interventions, diabetes can be prevented and reversed in the early stages or effectively managed for long-term health,” said Sujit Chakrabarty, Lillia’s founder and CEO. “Lillia exists to lower the chronic disease burden for the world by providing continuous adaptive care that drives a real and lasting lifestyle change.”
Lillia uses AI in conjunction with knowledgeable human coaches, such as psychologists, dietitians, and physicians, to develop a care plan that is hyperlocalized to a person’s metabolism and way of life. It helps them form enduring microhabits supported by validated clinical results.
Lillia also presented its vision of a chronic care digital twin combined with AI agents at Web Summit Qatar. This will enable applications in real-time risk monitoring, precision medication, and other use cases, as well as provide predictive capabilities to the platform.
Today, Lillia also revealed that the Qatar Research, Development, and Innovation (QRDI) Council has awarded it a $1.7 million grant to create the first chronic condition-focused digital twin in the GCC.
Nada Al-Olaqi, Director of Innovation Development and Piloting Programs at QRDI Council, said, “At QRDI Council, we’re proud to support Lillia as they push the boundaries of healthcare innovation with their AI-driven digital twin technology. Through our Technology Development Grant program, we empower pioneering companies like Lillia to bring transformative technology solutions to life, advancing healthcare, enhancing quality of life, and positioning Qatar as a leader in digital transformation. This partnership reinforces our shared commitment to creating a lasting impact for communities both locally and globally.”
Supported by investors like M Venture Partners, QSTP, and Qatar Development Bank, Lillia is growing quickly to become a world leader in AI-led chronic illness management. In the upcoming two years, the business intends to extend its offerings throughout Southeast Asia and the Middle East and North Africa.
Lillia has helped more than 40,000 people in the GCC and India with their weight-related issues and diabetes since 2020. Providing long-term clinical outcomes for up to 80% of patients enrolled on the platform, these services are provided in collaboration with 20 institutional clients in the public, corporate, insurance, and healthcare sectors.
“We are thrilled to collaborate with Lillia in our mission to lower diabetes rates and reduce healthcare costs for over 15,000 QLM members managing the condition. As we advance toward our vision of transforming healthcare from ‘Illness to Wellness,’ we eagerly anticipate the innovative AI-driven health solutions and systems they are developing,” said Mohammed Salem, Chief Business Officer, QLM Life and Medical Insurance.
“Lillia’s diabetes solution seamlessly integrates technology with an expert-driven behaviour change model—key to achieving optimal care outcomes in condition management.
As they evolve into an AI-first, adaptive care solution provider, we are excited to see how they leverage AI further to transform the management of lifestyle and chronic conditions,” said Rajdeep Ghosh, Chief Product and Technology Officer, Dr. Reddy’s Laboratories.
“Lillia brought in a strong technology platform, health experts, and excellent patient processes to support us in creating evidence-based interventions for diabetes and weight management. We achieved stellar clinical impact for 1000+ patients across 200+ nationwide clinics. As they push the boundaries of what technology and AI can do for health, we look forward to deepening our clinical impact together,” said Dr. Akshay Batra, Vice Chairman and MD, Dr. Batra’s Healthcare.
